Why the study?
Does enoxaparin dosage adjusted by anti-Factor Xa trough level reduce clinically evident venous thromboembolism in trauma patients?
Does enoxaparin dosage adjusted by anti-Factor Xa trough level reduce clinically evident venous thromboembolism in trauma patients?
Adjusting enoxaparin dosage based on anti-Xa trough levels may reduce VTE risk in trauma patients without increasing bleeding.
Anti-Xa-guided enoxaparin dosing may reduce VTE in trauma; hypothesis-generating and should not yet change practice.
In this study, subprophylactic anti-Xa trough levels were common in trauma patients. Enoxaparin dosage adjustment may lead to a reduced rate of VTE without an increased risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: